MX2016006270A - Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos. - Google Patents

Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Info

Publication number
MX2016006270A
MX2016006270A MX2016006270A MX2016006270A MX2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A MX 2016006270 A MX2016006270 A MX 2016006270A
Authority
MX
Mexico
Prior art keywords
compositions
cells
human placental
placental perfusate
subpopulations
Prior art date
Application number
MX2016006270A
Other languages
English (en)
Spanish (es)
Inventor
P Gurney Jodi
Zhang Xiaokui
Herb Stacy
J Hariri Robert
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of MX2016006270A publication Critical patent/MX2016006270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2016006270A 2013-11-15 2014-11-14 Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos. MX2016006270A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361905076P 2013-11-15 2013-11-15
US201361905077P 2013-11-15 2013-11-15
PCT/US2014/065665 WO2015073800A2 (en) 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Publications (1)

Publication Number Publication Date
MX2016006270A true MX2016006270A (es) 2016-09-07

Family

ID=53058264

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006270A MX2016006270A (es) 2013-11-15 2014-11-14 Composiciones que comprenden células perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.
MX2021003799A MX2021003799A (es) 2013-11-15 2016-05-13 Composiciones que comprenden celulas perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003799A MX2021003799A (es) 2013-11-15 2016-05-13 Composiciones que comprenden celulas perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.

Country Status (11)

Country Link
US (2) US20160279171A1 (https=)
EP (1) EP3068432A4 (https=)
JP (4) JP2016537362A (https=)
KR (3) KR20240023709A (https=)
CN (2) CN105916521A (https=)
AU (3) AU2014348454A1 (https=)
CA (1) CA2930573C (https=)
MX (2) MX2016006270A (https=)
RU (1) RU2016123361A (https=)
WO (1) WO2015073800A2 (https=)
ZA (1) ZA201603270B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707491B2 (en) * 2016-11-11 2023-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of treating neurodegenerative disorders
EP4417210A1 (en) * 2017-03-15 2024-08-21 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
KR20210111244A (ko) * 2018-11-30 2021-09-10 셀룰래리티 인코포레이티드 태반-유래 동종이계 car-t 세포 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP3246396B1 (en) * 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2005094353A2 (en) * 2004-03-29 2005-10-13 Cytomatrix, Llc Methods for production of regulatory t cells and uses thereof
DK1957633T3 (en) * 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
CN101389754A (zh) 2005-12-29 2009-03-18 人类起源公司 胎盘干细胞和第二来源干细胞的联合培养
PT2471904T (pt) 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
NZ570614A (en) * 2006-01-23 2012-07-27 Athersys Inc Multipotent adult progenitor cell treatment of brain injuries and diseases
EP2023717B1 (en) * 2006-05-11 2016-04-13 Anthrogenesis Corporation Methods for collecting placenta cord blood stem cells
ZA200902233B (en) * 2006-10-23 2010-07-28 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations
AU2008216748A1 (en) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and CD34+, CD45- placental stem cell-enriched cell populations
EP2164953A4 (en) * 2007-06-18 2010-06-30 Childrens Hosp & Res Ct Oak METHOD OF ISOLATING STAIN AND PRECIPITATING CELLS FROM PLAZENTA
CA2700613C (en) * 2007-09-26 2022-09-20 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
NZ599825A (en) 2007-09-28 2014-10-31 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
NZ592839A (en) 2008-11-21 2012-10-26 Anthrogenesis Corp Treatment of diseases, disorders or conditions of the lung using placental cells
WO2010105144A2 (en) * 2009-03-12 2010-09-16 University Of South Florida Method of disease-induced and receptor-mediated stem cell neuroprotection
US20100323446A1 (en) * 2009-06-05 2010-12-23 Jill Renee Barnett Method of collecting placental cells
US20120177618A1 (en) * 2009-07-14 2012-07-12 Massachusetts Institute Of Technology Hematopoietic stromal progenitor cells and uses thereof
US20110280849A1 (en) 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
LT2556145T (lt) * 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
ES2666746T3 (es) * 2010-07-13 2018-05-07 Anthrogenesis Corporation Métodos para generar linfocitos citolíticos naturales
MX2013006592A (es) * 2010-12-17 2014-02-06 Anthrogenesis Corp Tratamiento de lesion de la medula espinal y lesion traumatica de cerebro empleando celulas adherentes obtenidas del amnios.
KR20130128438A (ko) * 2010-12-17 2013-11-26 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
US20120171180A1 (en) 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising amnion derived adherent cells and platelet-rich plasma
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
JP2015526088A (ja) * 2012-08-13 2015-09-10 アントフロゲネシス コーポレーション ナチュラルキラー細胞及びその使用
EP2909314B1 (en) 2012-10-19 2020-12-02 Celularity, Inc. Treatment of pain using amnion derived adherent cells

Also Published As

Publication number Publication date
US20160279171A1 (en) 2016-09-29
KR20240023709A (ko) 2024-02-22
AU2022215291A9 (en) 2022-11-24
EP3068432A4 (en) 2017-04-19
CA2930573A1 (en) 2015-05-21
JP2016537362A (ja) 2016-12-01
AU2022215291A1 (en) 2022-09-01
WO2015073800A2 (en) 2015-05-21
ZA201603270B (en) 2022-09-28
CN105916521A (zh) 2016-08-31
JP2022020622A (ja) 2022-02-01
CN113679740A (zh) 2021-11-23
RU2016123361A (ru) 2017-12-20
JP2024016037A (ja) 2024-02-06
AU2020202182A1 (en) 2020-04-16
KR20210121277A (ko) 2021-10-07
AU2014348454A1 (en) 2016-06-02
JP2020019777A (ja) 2020-02-06
WO2015073800A8 (en) 2015-12-17
KR20160098244A (ko) 2016-08-18
US20190117705A1 (en) 2019-04-25
EP3068432A2 (en) 2016-09-21
CA2930573C (en) 2023-12-05
MX2021003799A (es) 2021-06-04
WO2015073800A3 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
MX2023001226A (es) Anticuerpos anti-lag-3.
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MX2018015656A (es) Compuestos heterociclicos como antibacterianos.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
PH12015502767A1 (en) Sc-� cells and compositions and methods for generating the same
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201890201A1 (ru) Антибактериальные соединения
MX2014006514A (es) Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
NZ709215A (en) Compositions comprising anti-cd38 antibodies and lenalidomide
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2024001617A (es) Composiciones biofarmaceuticas.
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
MX356163B (es) Anilinas sustituidas como antagonistas de ccr(4).
MX381278B (es) Composición para la estimulación ovárica controlada.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
NZ741785A (en) 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv
WO2016048861A3 (en) Heterocyclic compounds and use thereof
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX384259B (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2021003799A (es) Composiciones que comprenden celulas perfundidas de placenta humana, subpoblaciones de las mismas y sus usos.